RE:RE:RE:Positivity vs rollback
The question then remains with a rollback imminent for RP... where do we see the SP going? Shiseido is currently planning a commercial launch of RCH-01 in 2018 although they've loosely discussed the potential to do so earlier. "With sufficient funding, Replicel also has the opportunity to complete the building and validation testing of the commercial-grade prototypes of its next-generation dermal injector devices which "could" be market-ready and the subject of a licensing deal by late 2017."
How do we foresee the market responding to a $1.00 SP when it looks like we are at least 12 months out from some of these projections "if" and "when" they materialize. ?
I am humbly soliciting an opinion on this one as none of us have a crystal ball. I appreciate the posts and responses thus far.